Skip to content
cccskills
FreePublished on GitHub

endo-csii-suggest-t2dm-poor-control-despite-intensive

Suggests CSII with good adherence to monitoring and dosing for adults with type 2 diabetes mellitus who have poor glycemic control despite intensive insulin therapy, oral agents, other injectable therapy, and lifestyle modifications. Trigger phrases include 'T2DM on multiple injectables still uncontrolled' and 'Consider pump for insulin-requiring T2DM failing other therapies'.

The English summary is being prepared. Showing the original description.

Run score Not tested

See how to install

Files included (1)

  • SKILL.md2.6 KB

SKILL.md (original)

Review the instructions the agent will receive before you install.

Suggest CSII for T2DM with poor control despite intensive therapy

STEP 1 — Gather Information

Collect current regimen: insulin type/dose (basal-bolus MDI), oral agents (e.g., metformin), other injectables (GLP-1 RA, basal insulin), lifestyle changes, adherence, A1C, hypoglycemia episodes, glucose variability, patient willingness/ability to perform site changes and carb counting, education/support availability, comorbidities.

STEP 2 — Rule In / Rule Out

Is the patient on intensive insulin therapy (basal-bolus MDI) plus oral agents and/or other injectables with lifestyle modifications yet still has poor glycemic control (e.g., A1C >7.5‑8.0%)? If YES, proceed; if NO, optimize current therapy before considering CSII.

STEP 3 — Classify or Stratify

Assess suitability for CSII: adequate dexterity/vision, cognitive ability, willingness to perform frequent glucose monitoring, carbohydrate counting, and infusion site care; absence of uncontrolled psychiatric illness or substance abuse; reliable follow‑up access. Classify as suitable if criteria met.

STEP 4 — Decide

If suitable, initiate CSII with comprehensive education/training on pump operation, bolus calculator use, site rotation, and hypoglycemia/DKA prevention; schedule frequent follow‑up to review data and adjust settings.

Clinical Guardrails / Mimics / Pitfalls

Do not offer CSII to patients unable to perform self‑care tasks, lacking education/support, or with unrealistic expectations; avoid as first‑line before maximizing oral/GLP‑1/basal insulin; monitor for infusion site infections, lipohypertrophy, and DKA risk from pump failure; consider cost/access barriers.

Concrete Clinical Example

A 58‑year‑old on basal glargine 40 U qd, prandial lispro sliding scale, metformin 1000 mg BID, liraglutide 1.8 mg daily, with A1C 9.2% despite adherence, is motivated, passes carb‑counting and site‑care assessment, and has regular follow‑up; CSII is suggested with training.

Source: Diabetes Technology—Continuous Subcutaneous Insulin Infusion Therapy and Continuous Glucose Monitoring in Adults, Endocrine Society, 2016, DOI:10.1210/jc.2016-2534

Reviews

No reviews yet. Tell others what you thought.

Comments

No login needed. Share how it worked for you, ask a question, or note where it did not run.

No comments yet. Be the first to write one.

Comments are published right away. Do not include personal information such as email addresses or phone numbers. Up to 2 URLs.

0 / 1,000 characters

This form is protected by reCAPTCHA, and the Google Privacy Policy and Terms of Service apply.

More skills from this repository

Guide pump setting adjustments for the MiniMed 780G system based on CareLink data, using Medtronic's 3-step follow-up workflow. Use when a clinician has CareLink data for a 780G patient and wants to know what to change — which setting, by how much, and how to program it. Triggers include: "what do I adjust", "how to fix high TIR", "how to reduce hypos", "adjust ICR/ISF/basal", "SmartGuard settings", "780G pump settings review", or any question about optimising 780G therapy after reviewing a download.

The English summary is being prepared. Showing the original description.

dromlakhani/MD2SKILL14Updated Oct 20, 2026

Performs corticotropin stimulation test to diagnose adrenal insufficiency when morning cortisol is indeterminate (3-15 µg/dL). Triggers include morning cortisol 3-15 µg/dL requiring further AI testing.

The English summary is being prepared. Showing the original description.

dromlakhani/MD2SKILL14Updated Oct 20, 2026

Administers immediate parenteral injection of 50–100 mg hydrocortisone for suspected adrenal crisis secondary to adrenal insufficiency. Triggers include hypotension, hypoglycemia, or acute illness in a patient with known adrenal insufficiency.

The English summary is being prepared. Showing the original description.

dromlakhani/MD2SKILL14Updated Oct 20, 2026

Clinicians educate adrenal insufficiency patients taking nondexamethasone glucocorticoids who initiate enzyme-inducing antiepileptic drugs about early signs of adrenal insufficiency. Trigger when an AI patient on nondexamethasone GC starts an enzyme-inducing AED such as phenytoin, carbamazepine, or oxcarbazepine.

The English summary is being prepared. Showing the original description.

dromlakhani/MD2SKILL14Updated Oct 20, 2026

In central hypothyroidism patients receiving levothyroxine who initiate enzyme‑inducing antiepileptic drugs, the guideline recommends checking free T4 at least 6 weeks after AED start and increasing the levothyroxine dose if free T4 falls below the target range. Triggers include: central hypothyroidism patient on levothyroxine starting antiepileptic drug such as phenytoin, carbamazepine, or oxcarbazepine.

The English summary is being prepared. Showing the original description.

dromlakhani/MD2SKILL14Updated Oct 20, 2026

Applies serum cortisol cutoffs (<3 μg/dL indicates central adrenal insufficiency; >15 μg/dL likely excludes it) when evaluating morning cortisol for suspected adrenal insufficiency. Triggers include morning cortisol measurement in suspected AI and use when interpreting morning cortisol levels for adrenal insufficiency workup.

The English summary is being prepared. Showing the original description.

dromlakhani/MD2SKILL14Updated Oct 20, 2026

See all skills by dromlakhani

Report a problem with this skill